Toyobo Co., Ltd.
Notice of Recording Extraordinary Loss (Impairment Loss) and Revision of Full-Year Consolidated Earnings Forecast
An impairment loss has been recorded as an extraordinary loss, and the full-year consolidated earnings forecast has been revised. The impairment amount is 6.5 billion yen. Sales, operating income and ordinary income are expected to exceed the previous forecasts, but net income attributable to owners of parent is expected to fall short of the previous forecast.
Key Figures
- Extraordinary loss (impairment loss): 6.5 hundred million yen
- Results for fiscal year ended March 2026 (for reference): Net sales 421,563 million yen, Operating income 27,906 million yen, Ordinary income 22,878 million yen, Net income attributable to owners of parent -3,000 million yen
- Full-year consolidated earnings forecast: Net sales and income expected to exceed previous forecast, net income expected to be below previous forecast
AI要約
Recording of Extraordinary Loss and Revision of Full-Year Forecast
The Company recorded an extraordinary loss (impairment loss) in the second quarter of the fiscal year ending March 2027. The impairment amount is 6.5 billion yen, attributable to the write-down of the recoverable amount of assets related to the pharmaceutical contract manufacturing business to their recoverable amount. As a result, the Company revised its full-year consolidated earnings forecast; net sales, operating income and ordinary income are expected to exceed the previous forecasts, while net income attributable to owners of parent is expected to be below the previous forecast.
Outlook and Notes
This forecast is based on information available as of the announcement date and actual results may vary due to future factors. Investors should monitor developments closely because the occurrence of the extraordinary loss and future revisions to business plans may have an impact.
Toyobo Co., Ltd.
Company overview · Stock price · Financial data · All IR
